Am J Obstet Gynecol. 2023 Jun;228(6):B2-B10. doi: 10.1016/j.ajog.2023.02.018. Epub 2023 Feb 28.
Cerclage is the mainstay of treatment for cervical insufficiency. Although transabdominal cerclage may have advantages over transvaginal cerclage, it is associated with increased morbidity and the need for cesarean delivery. In this Consult, we review the current literature on the benefits and risks of transabdominal cerclage and provide recommendations based on the available evidence. The following are Society for Maternal-Fetal Medicine recommendations: (1) we recommend that transabdominal cerclage placement be offered to patients with a previous transvaginal cerclage placement (history or ultrasound indicated) and subsequent spontaneous singleton delivery before 28 weeks of gestation (GRADE 1B); (2) we recommend maternal-fetal medicine consultation for counseling patients who may be candidates for transabdominal cerclage and those who have undergone transabdominal cerclage (Best Practice); (3) we suggest that both laparoscopic transabdominal cerclage and open transabdominal cerclage are acceptable and the decision of approach may depend on gestational age, technical feasibility, available resources, and expertise (GRADE 2B); (4) we suggest that transabdominal cerclage can be performed before pregnancy or in the first trimester of pregnancy with similar fetal outcomes. If a patient with an indication for transabdominal cerclage presents after the first trimester of pregnancy, transabdominal cerclage can still be considered before 22 weeks of gestation (GRADE 2C); (5) we recommend that routine transvaginal cervical length screening not be performed for patients with a transabdominal cerclage in situ (GRADE 1C); (6) we suggest that for individuals at risk of recurrent spontaneous preterm birth, including those with a transabdominal cerclage in situ, a risk-benefit discussion of supplemental vaginal progesterone be undertaken with shared decision-making (GRADE 2C); (7) we suggest that pregnancy loss be managed with dilation and curettage or dilation and evacuation with a transabdominal cerclage in situ or via usual obstetrical management after laparoscopic removal of the transabdominal cerclage, depending on gestational age and resources available (GRADE 2C); and (8) we suggest cesarean delivery between 37 0/7 and 39 0/7 weeks of gestation for patients with a transabdominal cerclage in situ (GRADE 2C).
环扎术是治疗宫颈机能不全的主要方法。虽然经腹环扎术可能优于经阴道环扎术,但它与发病率增加和需要剖宫产有关。在本次咨询中,我们回顾了经腹环扎术的益处和风险的现有文献,并根据现有证据提供了建议。以下是母胎医学学会的建议:(1)我们建议对有经阴道环扎术史或超声提示的经阴道环扎术史且随后在 28 孕周前发生自发性单胎分娩的患者行经腹环扎术(GRADE 1B);(2)我们建议对可能行经腹环扎术的患者和已行经腹环扎术的患者进行母胎医学咨询(最佳实践);(3)我们建议腹腔镜经腹环扎术和开腹经腹环扎术都是可接受的,手术方法的选择可能取决于孕周、技术可行性、可用资源和专业知识(GRADE 2B);(4)我们建议如果患者有经腹环扎术的指征,可在妊娠前或妊娠早期行经腹环扎术,且胎儿结局相似。如果有经腹环扎术指征的患者在妊娠早期后就诊,仍可考虑在 22 孕周前行经腹环扎术(GRADE 2C);(5)我们建议对原位经腹环扎术的患者不常规行经阴道宫颈长度筛查(GRADE 1C);(6)我们建议对有复发性自发性早产风险的个体,包括原位经腹环扎术的患者,与患者共同讨论补充阴道孕酮的风险获益,并进行决策(GRADE 2C);(7)我们建议对有原位经腹环扎术的患者,根据孕周和可用资源,可选择行刮宫术或扩宫和刮宫术,或在腹腔镜下取出经腹环扎术后行常规产科处理以终止妊娠(GRADE 2C);(8)我们建议对有原位经腹环扎术的患者在 37 0/7 至 39 0/7 孕周行剖宫产(GRADE 2C)。